Without comparative data to guide us, how do we decide between recommending ibrutinib or acalabrutinib? Here’s my take on which factors to consider in your patients with CLL or MCL.
Explore case scenarios followed by expert discussion and analysis of each case with distinguished experts William Wierda, MD, PhD, and Andrew Zelenetz, MD, PhD in this interactive video module.
In this downloadable slideset, William Wierda, MD, PhD, and Andrew Zelenetz, MD, PhD discuss CLL case challenges and the rationale and data supporting their treatment recommendations.
You are accessing CCO's educational content today as a Guest user.
If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.